CIVO® evaluates clinical response where it matters most—the patient's tumor
The CIVO (Comparative In Vivo Oncology) platform delivers multiplexed intratumoral microdosing, allowing clinical investigators to evaluate the localized tumor response to drug candidates in the tumor microenvironment while capturing tumor heterogeneity and patient diversity.
A safe, validated research protocol
CIVO offers a microscopic view of the direct interactions between the investigational assets and the tumor in situ. Not only are the drug sites simple to identify, but responses are easy to observe, interpret, and are consistent with expected clinical responses.
- Immune profiles
- PD biomarkers
- Microenvironment impact
- Drug combination potential
- Responder hypotheses
Fundamentally changing cancer drug development
In a few simple steps, this patented process can simultaneously evaluate multiple drugs or drug combinations using 100+ assays for tumor and microenvironment responses.
CIVO injects drug microdoses directly into a patient's tumor. The device delivers trackable drug "columns."
Drugs interact with the tumor while still within the patient. Then the tumor is surgically removed.
The tumor tissue is processed by sectioning crosswise to the drug columns. Four-micron sections are then cut and placed onto slides for staining.
Tumor slices are assessed for response around each injection site using CIVOanalyzer™.
CIVOanalyzer™ delivers automated response quantification via radial distance calculations, effectively comparing responses between drugs and drug combinations.
CIVO: Designed to solve a long-standing challenge
The importance of designing specialized devices to deliver microdoses to solid tumors in situ has been recognized by lawmakers and researchers alike.
Microdosing devices, like CIVO, were recognized by the Moonshot Initiative: "if widely implemented, [it] could revolutionize the way in which drug combinations are tested…"1 and help accelerate early-stage drug development.
“…delivery of cancer drugs directly into tumors in vivo can indicate cancer sensitivity; if implemented in clinical practice, these devices have the potential to reduce indiscriminate drug use, to improve survival, and to reduce unnecessary adverse effects.”2